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OBJECTIVE—Congenital hyperinsulinemic hypoglycemia is a
group of genetic disorders of insulin secretion most commonly
associated with inactivating mutations of the b-cell ATP-sensitive
K
+ channel (KATP channel) genes ABCC8 (SUR1) and KCNJ11
(Kir6.2). Recessive mutations of these genes cause hyperinsulin-
ism that is unresponsive to treatment with diazoxide, a channel
agonist. Dominant KATP mutations have been associated with
diazoxide-responsive disease. We hypothesized that some medi-
cally uncontrollable cases with only one KATP mutation might
have dominant, diazoxide-unresponsive disease.
RESEARCH DESIGN AND METHODS—Mutations of the KATP
genes were identiﬁed by sequencing genomic DNA. Effects of
mutations on KATP channel function in vitro were studied by
expression in COSm6 cells.
RESULTS—In 15 families with diazoxide-unresponsive diffuse
hyperinsulism, we found 17 patients with a monoallelic missense
mutation of SUR1. Nine probands had de novo mutations, two
had an affected sibling or parent, and four had an asymptomatic
carrier parent. Of the 13 different mutations, 12 were novel.
Expression of mutations revealed normal trafﬁcking of channels
but severely impaired responses to diazoxide or MgADP. Responses
were signiﬁcantly lower compared with nine SUR1 mutations
associated with dominant, diazoxide-responsive hyperinsulinism.
CONCLUSIONS—These results demonstrate that some domi-
nant mutations of SUR1 can cause diazoxide-unresponsive hy-
perinsulinism. In vitro expression studies may be helpful in
distinguishing such mutations from dominant mutations of SUR1
associated with diazoxide-responsive disease. Diabetes 60:1797–
1804, 2011
I
nactivating mutations of the b-cell ATP-sensitive
K
+ channel (KATP channel) are the most common
cause of hypoglycemia due to congenital hyperin-
sulinism (1). These mutations occur in either of the
two subunits of the KATP channel, SUR1 and Kir6.2, which
are encoded by two adjacent genes on chromosome 11p,
ABCC8 and KCNJ11 (2,3). Infants with recessive muta-
tions of these genes typically have complete loss of KATP
channel function affecting all of their b-cells. Recessive
KATP mutations can also cause focal hyperinsulinism
through a mechanism of postzygotic loss of heterozygosity
for the maternal 11p region, leading to isodisomy for
a paternally transmitted mutation (4). Recessive ABCC8
and KCNJ11 mutations are usually null mutations or are
amino acid substitutions that prevent trafﬁcking of chan-
nels to the plasma membrane, thus leading to persistent
plasma membrane depolarization and insulin release (5,6).
Because diazoxide suppresses insulin secretion by acting
as a KATP channel agonist to prevent membrane depolari-
zation, most children with such mutations of the KATP genes
are not responsive to treatment with diazoxide.
In contrast to these well-recognized recessive mutations
of the KATP channel, we and others have described chil-
dren who have mutations of ABCC8 and KCNJ11 that are
expressed in dominant fashion (7–9). In most of these
cases, the hypoglycemia could be controlled with di-
azoxide, consistent with retention of residual channel ac-
tivity. All of the dominant KATP mutations associated with
hyperinsulinism involve amino acid changes which, in the
cases tested, could be shown by in vitro expression stud-
ies to permit normal trafﬁcking of mature channels to
the plasma membrane. However, the resultant channels
had impaired responses to agonists, such as MgADP and
diazoxide (7).
We have recently completed genetic analyses on a large
group of diazoxide-unresponsive congenital hyperinsulin-
ism patients seen at the Children’s Hospital of Phila-
delphia. In most cases with identiﬁed mutations, the
children either had diffuse disease with recessively in-
herited mutations of the KATP genes or had focal lesions
isodisomic for a paternally derived recessive KATP mutation.
However, in a subset of diffuse, diazoxide-unresponsive
cases, only a single mutation in ABCC8 was detected. We
hypothesize that these are dominantly acting mutations
that cause a diazoxide-unresponsive form of hyperinsu-
linism. This report describes the clinical features of the
affected children and evidence from in vitro expression
studies that distinguish the diazoxide-unresponsive from
the diazoxide-responsive forms of dominant KATP hyper-
insulinism.
RESEARCH DESIGN AND METHODS
The case subjects described in this study come from a large group of children
with hyperinsulinism who were referred to The Children’s Hospital of Phila-
delphia between 1990 and 2010. The diagnosis of hyperinsulinism was based
on previously described criteria: fasting hypoglycemia accompanied by in-
adequate suppression of plasma insulin, inappropriately low plasma free fatty
acid and plasma b-hydroxybutyrate concentrations, and an inappropriate in-
crease in serum glucose levels after administration of glucagon injection at the
time of hypoglycemia (10,11). Age of onset was deﬁned as the age of ﬁrst
symptoms of hypoglycemia. Patients were deﬁned as being unresponsive to
diazoxide if hypoglycemia could not be controlled by treatment with 15 mg/kg/day
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ORIGINAL ARTICLEdiazoxide for a minimum of 5 days (i.e., able to keep blood glucose .70 mg/dL
for more than 8–10 h of fasting). Most of these diazoxide-unresponsive patients
required surgical pancreatectomy.
Mutation analysis.Genomic DNAwasisolated from peripheral blood samples
of patients and family members (5 PRIME, Gaithersburg, MD). Where pe-
ripheral blood was not available, saliva was collected via the Oragene DNA
Self Collection kit (DNA Genotek, Kanata, Ontario, Canada) and extracted
according to the manufacturer’s protocol. DNA was extracted from surgical
pancreatic specimens using the DNA/RNA Allprep kit (Qiagen, Valencia, CA).
The coding sequences and intron/exon splice junctions of the ABCC8 and
KCNJ11 genes were ampliﬁed and directly sequenced on an ABI 3730 capil-
lary DNA analyzer (Applied Biosystems, Carlsbad, CA). Resulting chromato-
grams were analyzed with the Sequencher 4.9 program (Gene Codes, Ann
Arbor, MI). The nucleotides of the ABCC8 gene and the translated amino acids
were numbered according to the sequence reported by Nestorowicz et al. (2)
that includes the alternatively spliced exon 17 sequence (NCBI accession no.
L78224). Putative mutations were analyzed with mutation prediction software
SIFT (12) and Polyphen (13) and were also screened in DNA from 50 control
subjects (Coriell Cell Depository, Camden, NJ) to rule out the possibility of
rare polymorphisms.
Exonic dosage assays. TaqMan Copy Number assays (Applied Biosystems/
Life Technologies, Carlsbad, CA) were used to test for intragenic deletions/
insertions that may have been missed by direct sequencing. Custom assays
were designed for exons in which no suitable predesigned assay was found.
Real-time PCR was performed on genomic DNA using an ABI Prism 7900HT
Sequence Detection system and analyzed using SDS software (version 2.3;
Applied Biosystems/Life Technologies). Applied Biosystems CopyCaller Soft-
ware (version1.0) was usedtodetermine thecopy numberof each exonin each
sample. Assays were run in quadruplicate for case subjects with two control
samples and a negative control subject for each assay.
Functional analysis of mutant channels. Point mutations were introduced
into hamster SUR1 cDNA in the pECE plasmid using the QuikChange muta-
genesis kit (Agilent Technologies, Santa Clara, CA) and conﬁrmed by DNA
sequencing (5). COSm6 cells were transfected with wild-type or mutant SUR1
and wild-type rat Kir6.2 cDNA (in pCDNAI) using FuGene6 and subjected to
analysis by Western blot, immunoﬂuorescence staining, and a quantitative
chemiluminescence assay 48–72 h post-transfection as previously described
(14). For these experiments, a SUR1 tagged with a FLAG-epitope at the NH2-
terminus (denoted as ﬂag-SUR1 hereinafter) was used. The FLAG tag has been
shown not to affect channel expression and function (15). For Western blot-
ting, cells were lysed in 20 mmol/L Hepes, pH 7.0/5 mmol/L EDTA/150 mmol/L
NaCl/1% Nonidet P-40 with protease inhibitors. Proteins were separated by
SDS-PAGE (8%), transferred to nitrocellulose, probed with M2 anti-FLAG
antibody (Sigma, St. Louis, MO) followed by horseradish peroxidase (HRP)-
conjugated anti-mouse secondary antibodies, and visualized by enhanced
chemiluminescence (Super Signal West Femto; Pierce). For surface staining,
living cells were incubated with anti-FLAG antibody for 1 h at 4°C. Cells
were then ﬁxed with cold (220°C) methanol for 10 min, incubated with Cy-3
conjugated anti-mouse secondary antibodies for 30 min at room temperature,
and viewed with an Olympus Fluoview confocal microscope. For chemi-
luminescence assays, cells were ﬁxed with 2% paraformaldehyde for 30 min at
4°C, preblocked in PBS/0.1% BSA for 30 min, incubated in M2 anti-FLAG
antibody for an hour, washed 4 3 30 min in PBS/0.1% BSA, incubated in
HRP-conjugated anti-mouse for 20 min, and washed again 4 3 30 min in PBS/
0.1% BSA. Chemiluminescence was quantiﬁed using a TD-20/20 luminometer
(Turner Designs) following 5-s incubation in Power Signal Elisa Femto luminol
solution (Pierce).
Functionalpropertiesofchannelswerestudiedusinginside-outpatch-clamp
recordings (14). COSm6 cells transfected with KATP channel subunits and the
green ﬂuorescent protein (to identify transfected cells) cDNAs were plated
onto coverslips and recorded 48–72 h posttransfection using micropipettes
with resistance ;1.0–1.5 MV. The bath and pipette solution (K-INT) contained
the following: 140 mmol/L KCl, 10 mmol/L K-HEPES, and 1 mmol/L K-EGTA,
pH 7.3. ATP and ADP were added as the potassium salt. Currents were mea-
sured at membrane potential of 250 mV and inward currents shown as up-
ward deﬂections. Data were analyzed using pCLAMP software (Molecular
Devices, Sunnyvale, CA). The MgADP or diazoxide response was calculated
as the current in K-INT solution plus 0.1 mmol/L ATP, 0.5 mmol/L ADP or
0.2 mmol/L diazoxide, and 1 mmol/L free Mg
2+ relative to that in plain K-INT
solution.
Statistical analyses. To compare the differences in diazoxide and MgADP
stimulation between the diazoxide-responsive and diazoxide-unresponsive
groups, a nonparametric Mann-Whitney U test was performed using GraphPad
InStat (version 3.0b for Macintosh; GraphPad Software, San Diego, CA).
Consent. Written informed consent was obtained from patients’ parents for
this study. The study was reviewed and approved by The Children’s Hospital
of Philadelphia Institutional Review Board.
Illustrative case subject. The proband in Family 2 (Fig. 1), now aged 6 years,
was the 1,760-g large-for-gestational-age (LGA) product of a 28-week preg-
nancy, delivered by cesarean section. During the pregnancy, the proband’s
mother was treated with insulin for diabetes resulting from a subtotal pan-
createctomy at 3 months of age for congenital hyperinsulinism (see below).
Hypoglycemia was identiﬁed at birth (blood glucose 21 mg/dL), initially
attributed to the maternal diabetes. The hypoglycemia remained difﬁcult to
control (maximal glucose infusion rate of 37 mg/kg/min). A diagnosis of hy-
perinsulinism was made based on multiple elevated insulin levels at times of
hypoglycemia (99, 94, and 125 mU/mL). Diazoxide treatment (17.6 mg/kg/day)
was begun at 4 days of age but failed to control the hypoglycemia. Addition of
octreotide (33 mg/kg/day) and 1 mg/day glucagon infusion were also in-
effective. On day of life 27, the infant was transferred to the Children’s Hos-
pital of Philadelphia for pancreatectomy because of intractable hypoglycemia.
At surgery, biopsies of the pancreas were consistent with diffuse hyperinsu-
linism (islets in multiple areas showed evidence of nucleomegaly in a small
percentage of b-cells). A 98% pancreatectomy was performed. At discharge,
insulin was brieﬂy needed for hyperglycemia, but the proband was sub-
sequently hypoglycemic and able to tolerate fasts of only 6 h.
Four years later, the proband’s brother was born weighing 1,000 g, ap-
propriate for gestational age (AGA), after 27 weeks’ gestation. The initial blood
glucose was low, 44 mg/dL, and the insulin was elevated, 189 mU/mL. This
infant also required a high rate of dextrose infusion to control hypoglycemia
(23 mg/kg/day). He was treated with diazoxide (15 mg/kg/day for 5 days) and
subsequently with octreotide without improvement of his hypoglycemia. At
10 weeks of age, a near-total pancreatectomy was performed and histology
revealed diffuse hyperinsulinism.
The proband’s mother presented at 3 months of age with a hypoglycemic
seizure and required a 95% pancreatectomy for uncontrolled hyperinsulinism.
At 5 years of age, she developed insulin-requiring diabetes. She was 20 years
of age at the time of her ﬁrst delivery, and her pregnancies were complicated
by poor diabetes control, edema, hypertension, and diabetic nephropathy with
proteinuria.
Direct sequencing of genomic DNA from the proband, his affected mother,
and younger brother revealed a single heterozygous A478D mutation in exon 9
of ABCC8 (SUR1) (Fig. 1).
RESULTS
Direct sequencing of the two KATP channel genes, ABCC8
and KCNJ11, on patients with diazoxide-unresponsive
congenital hyperinsulinism seen at The Children’s Hospital
of Philadelphia between 1990 and 2010 identiﬁed muta-
tions in 232 cases. Most of these were patients with diffuse
disease who were biallelic for recessive mutations or were
patients with focal hyperinsulinism who were monoallelic
for a paternal mutation. However, in 17 children from 15
families, monoallelic missense amino acid substitutions
were found that appeared to be responsible for diazoxide-
unresponsive hyperinsulinism through an autosomal domi-
nant mode of expression. As shown in Fig. 1 and Table 1,
a total of 13 different missense mutations were found in
the 15 families. The mutations all affected the ABCC8
gene, which encodes the SUR1 subunit of the b-cell KATP
channel. These apparently dominant SUR1 mutations
accounted for 17% of diffuse cases associated with ABCC8
mutations and 16% of total diffuse cases with KATP muta-
tions. Twelve of the mutations were novel; the S1387F
mutation has been previously reported in a patient who was
heterozygous for this single mutation and had diazoxide-
unresponsive diffuse hyperinsulinism (16). We are aware
of a third case with the S1387F mutation and diazoxide-
unresponsive hyperinsulinism. None of the 13 mutations
were identiﬁed in 100 normal alleles. SIFT and Polyphen
predicted that only the Q1459H substitution would be tol-
erated. In 7 of the 15 families (families 2, 9–11, and 13–15),
copy number variation assays excluded the existence of
intragenic insertions or deletions on the other allele that
would have been missed by direct sequencing. Mutation
analysis of genomic DNA isolated from pancreatic surgi-
cal specimens (families 3, 7–8, 12, and 13) conﬁrmed the
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second KATP mutations.
Table 1 compares the clinical features of the 17 children
with diazoxide-unresponsive, dominant SUR1 mutations
with patients with diazoxide-responsive, dominant KATP
mutations, and with patients with typical diffuse disease
due to biallelic recessive mutations. The majority of the
diazoxide-unresponsive, dominant patients were LGA, which
was similar to the other two groups of patients. The median
age at presentation was similar to that of the group with
recessive mutations but was earlier than that in the
diazoxide-responsive dominant group, suggesting a more
severe form of hyperinsulinism. Fifteen of the 17 diazoxide-
unresponsive, dominant cases required near-total pancre-
atectomy to control their hypoglycemia; two patients were
treated with octreotide and frequent feeds. All of the 15
patients who underwent surgery had histologic evidence
of diffuse hyperinsulinism as evidenced by islets contain-
ing enlarged nuclei throughout the pancreas.
Four of the mutations, shown in Fig. 1, were present in
multiple affected individuals, consistent with dominant
inheritance. These include the mother and her two sons
in family 2 and two siblings in family 3. The V715G muta-
tion occurred in three different, unrelated probands; in
two of these, the mutation was de novo. As noted above,
the S1387F mutation has also been found in multiple
affecteds. Three of the four parents who carried a muta-
tion were asymptomatic; however, one of these parents
had a sibling with a history of childhood seizures and re-
tardation consistent with symptomatic hypoglycemia
(family 13). Half of the probands (9 of 17) had de novo
mutations. Two additional case subjects, with the V715G
and G716D mutations, may also be de novo mutations;
however, DNA was available on only one of the parents
for genetic testing. Overall, a dominant mode of in-
heritance could be conﬁrmed for 5 of the 13 mutations.
The others also appear to be dominant based on func-
tional assays of the mutations. (See below.)
Figure 2 illustrates the predicted location of the domi-
nant, diazoxide-unresponsive mutations in the SUR1 pro-
tein (17,18). Most are clustered in the second nucleotide
binding fold of SUR1, where many of the known dominant,
diazoxide-responsive mutations are also located. Several
of the diazoxide-unresponsive mutations affect the same
or closely adjacent residues that are also affected by
diazoxide-responsive mutations (e.g., S1384, S1387, S1389,
and E1517). However, four of the diazoxide-unresponsive
mutations cluster around the Walker A and B motifs of the
FIG. 1. Pedigrees of families with dominant, diazoxide-unresponsive mutations of SUR1. The pedigrees are listed in ascending order of SUR1
codons. Fraternal twins are indicated by diagonal lines connecting the offspring to the parents. Arrows indicate probands. Black shapes, hypo-
glycemia diagnosed; diagonal lines, asymptomatic carrier; and ﬁlled gray, suspected hypoglycemia. n/M, mutation positive; n/n, mutation negative.
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responsive mutations occur. The V715 and S1387 codons
are mutated to multiple different amino acids that cause
diazoxide-unresponsive disease.
Functional testing was performed on these dominant,
diazoxide-unresponsive mutations in COSm6 cells. First,
Western blots and surface immunoﬂuorescence staining
were used to determine whether the mutant channels were
appropriately glycosylated and transported to the cell
surface. Figure 3 shows an example of one of the domi-
nant, diazoxide-unresponsive mutations, S1387Y. The S1387Y
mutant channels are correctly glycosylated and trans-
ported to the plasma membrane surface like wild-type
channels and like the dominant, diazoxide-responsive mu-
tation R1539E (Fig. 3A and B). Next, channel responses to
the metabolic regulator MgADP (Fig. 3C) and the channel
agonist diazoxide (Fig. 3D) were evaluated using inside-out
patch-clamp electrophysiological recordings. As shown in
the representative traces and the averaged response from
multiple recordings (Fig. 3E), wild-type channels were well
stimulated by MgADP or diazoxide in the presence of in-
hibitory ATP (0.1 mmol/L). By contrast, the diazoxide-
responsive mutant R1539E had reduced, although still sig-
niﬁcant, residual response to both MgADP and diazoxide,
whereas the diazoxide-unresponsive mutant S1387Y com-
pletely lacked responses to MgADP and diazoxide. Under
the simulated heterozygous expression condition, the
diazoxide-responsive mutant R1539E also exhibited bet-
ter response to MgADP and diazoxide than the diazoxide-
unresponsive mutant S1387Y (Fig. 3E).
Table 2 summarizes the quantitative chemilumines-
cence surface expression and functional testing results
for the dominant, diazoxide-unresponsive mutations. All
13 missense mutations showed similar retention of ability
to trafﬁc to the membrane. However, once at the mem-
brane surface, the responses of the dominant, diazoxide-
unresponsive mutations to MgADP and diazoxide were
practically obliterated. Figure 4 compares the responses to
diazoxide and MgADP of channels expressing the diazoxide-
unresponsive and the diazoxide-responsive mutations. While
there was overlap between the two groups of mutations, the
diazoxide-responsive, dominant mutations retained sig-
niﬁcantly greater responses to effectors compared with the
TABLE 1
Clinical phenotype of patients with dominant, diazoxide-unresponsive SUR1 mutations
Birth
weight
Age of
presentation (days)
Diazoxide-
responsive Histology Mutation (p.) Parent of origin
Family 1 II-1 LGA 1 No Diffuse Q474R De novo
Family 2 II-1 LGA 1 No Diffuse A478D Maternal
Family 2 II-2 AGA 1 No Diffuse A478D Maternal
Family 3 II-1 AGA 1 No Diffuse V715A Maternal
Family 3 II-2 LGA 1 No No surgery V715A Maternal
Family 4 II-1 LGA 1 No No surgery V715G Not maternal
Family 5 II-1 LGA 1 No Diffuse V715G De novo
Family 6 II-1 LGA 42 No Diffuse V715G De novo
Family 7 II-1 LGA 5 No Diffuse G716D Not maternal
Family 8 II-1 AGA 3 No Diffuse T888P De novo
Family 9 II-1 AGA 2 No Diffuse G1384E De novo
Family 10 II-1 LGA 1 No Diffuse S1387F De novo
Family 11 II-1 LGA 1 No Diffuse S1387Y De novo
Family 12 II-1 LGA 1 No Diffuse S1389Y De novo
Family 13 II-1 SGA 180 No Diffuse A1458T Paternal
Family 14 II-1 LGA 88 No Diffuse Q1459H De novo
Family 15 II-1 AGA 167 No Diffuse E1517K Maternal
Dominant diazoxide-
unresponsive (n = 17)
65% LGA median 1 day range
(1–180 days)
100% no Diffuse 5 of 17 maternal
1 of 17 paternal
9 of 17 de novo
2 of 17 not maternal
Dominant diazoxide-
responsive (n = 13)
77% LGA median 30 days range
(1–1,215 days)
100% yes Diffuse 5 of 13 maternal
4 of 13 paternal
4 of 13 de novo
Recessive (n = 48) 87% LGA median 1 day range
(1–9 days)
100% no Diffuse 48 of 48 biallelic
LGA, AGA, SGA 5 large, appropriate, small for gestational age.
FIG. 2. Location of dominant, diazoxide-unresponsive (black circles)
and dominant, diazoxide-responsive (gray circles) mutations of SUR1
(7). Mutation locations are approximate based on current SUR1 to-
pology models (17,18). Secondary structures of SUR1 are shown, in-
cluding the amino (NH2-) and carboxy (COOH-) termini of the protein,
glycosylation sites, and nucleotide binding fold 1 (NBF1) and nucleo-
tide binding fold 2 (NBF2), which contain Walker A and B motifs (A and
B) associated with regulatory nucleotide binding.
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diazoxide, P = 0.0002).
DISCUSSION
In this group of children with congenital hyperinsulinism
who failed to respond to treatment with diazoxide, we
identiﬁed 13 mutations of the KATP channel that appear to
cause diffuse hyperinsulinism in an autosomal dominant
fashion. All of the mutations involved the ABCC8 gene that
encodes the SUR1 subunit of the channel. Evidence for
autosomal dominant expression included one example of
transmission from affected parent to affected child and
several examples of hyperinsulinism occurring in multiple
individuals sharing the same mutation. The clinical pheno-
type of hyperinsulinism in this disorder is indistinguishable
from that of children with the more common form of dif-
fuse hyperinsulinism due to two recessive KATP mutations,
including onset of symptomatic hypoglycemia at birth and
need for surgical pancreatectomy to control hypoglycemia.
However, the phenotype appeared to be more severe than
that seen in children with dominantly expressed KATP mu-
tations that are responsive to diazoxide, as reﬂected by
an earlier median age of onset. In vitro expression studies
showed that the mutations associated with diazoxide-
unresponsive hyperinsulinism produce SUR1 subunits
that can form channels with Kir6.2 that trafﬁc normally
to the plasma membrane—similar to mutations associated
FIG. 3. Functional analysis of mutant SUR1 expressed in COSm6 cells. A: Western blot analysis of mutant ﬂag-SUR1 proteins. COSm6 cells
were cotransfected with cDNAs for Kir6.2 and wild-type (WT) FLAG-SUR1, the diazoxide (Diaz)-responsive mutant R1539E FLAG-SUR1 or the
diazoxide-unresponsive mutant S1387Y FLAG-SUR1. Both mutants exhibit the lower core glycosylated band (solid arrow) and the upper complex
glycosylated band (open arrow) as seen in wild-type, indicating that the mutant proteins are processed correctly like the wild-type protein.
B: Immunoﬂuorescence staining of surface channels in COSm6 cells transfected with wild-type, R1539E, or S1387Y FLAG-SUR1 and wild-type
Kir6.2. Both mutants were well expressed at the cell surface like wild-type channels. C: Representative inside-out patch-clamp recordings of wild-
type, the diazoxide-responsive mutant R1539E, and the diazoxide-unresponsive mutant S1387Y show differences in MgADP response. Currents
were measured at –50 mV in symmetrical K-INT solution, and inward currents are shown as upward deﬂections. Patches were exposed to differing
concentrations of ATP and ADP, as indicated by the bars above the records. Free Mg
2+ concentration was maintained at 1 mmol/L in all ATP-
containing solutions. D: The same as in C except that channel response to diazoxide was compared. E: Quantiﬁcation of MgADP response (left
panel) and diazoxide response (right panel) using recordings shown in C and D. Currents were normalized to that seen in K-INT and expressed as
percentage of currents. Responses in both homozygous and simulated heterozygous expression conditions are shown. In the MgADP response
graph, each bar represents means 6 SEM of 16 wild-type and 4–6 mutant patches. In the MgADP response graph, each bar represents means 6 SEM
of 15 wild-type and 4–6 mutant patches. (A high-quality digital representation of this ﬁgure is available in the online issue.)
C.M. MACMULLEN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, JUNE 2011 1801with diazoxide-responsive dominant disease. However, the
diazoxide-unresponsive mutations produced a more severe
impairment in the expressed channel responses to activa-
tion by diazoxide and MgADP.
The thirteen dominant, diazoxide-unresponsive mutations
identiﬁed in this study are all missense mutations and were
primarily, but not exclusively, located in the ﬁrst and
second nucleotide-binding folds of the SUR1 subunit of the
KATP channel (Fig. 2). These mutation sites involve the
same regions or, in some cases, the same amino acid res-
idues as many of the dominant, diazoxide-responsive
mutations of SUR1, indicating that the two types of dom-
inant mutations cannot be distinguished by location alone.
They also affect the same regions as many of the known
recessively expressed mutations. It is interesting to note
that involvement of the Walker A and B sites of nucleotide
binding fold 1 appears to be limited to the diazoxide-
unresponsive dominant mutations, whereas both types of
dominant mutations can affect nucleotide binding fold 2.
Flanagan et al. (9) have also described three novel muta-
tions of SUR1 associated with diazoxide-unresponsive
hyperinsulinism that appear to act in an autosomal domi-
nant fashion. One of these mutations, D1506E, occurred in
an affected mother and child, conﬁrming dominant ex-
pression. The other two (G1485E and M1514K) occurred
de novo. These three mutations were located in the nu-
cleotide binding fold 2 of SUR1. In the current study, seven
of the thirteen diazoxide-unresponsive, dominant mutations
were also located in the nucleotide binding fold 2; however,
this was not the only region of SUR1 affected by these types
of defects (see Fig. 2). It is also interesting to note that,
although three of the fourteen diazoxide-responsive domi-
nant mutations that we previously reported involved the
Kir6.2 subunit (7), to date diazoxide-unresponsive defects
have exclusively involved SUR1.
The important distinction between dominant and recessive
missense mutations of the ABCC8 gene that cause hyperin-
sulinism appears to be whether they produce SUR1 subunits
that can combine with Kir6.2 and then be trafﬁcked to the
TABLE 2
Mutant protein biogenesis and activity
Surface expression
(% of wild-type channel level)
MgADP stimulation
(% current in 0.1 mmol/L ATP
plus 0.5 mmol/L ADP)
Diazoxide stimulation
(% current in 0.1 mmol/L ATP
plus 0.2 mmol/L diazoxide)
Mutation
1) Q474R 119.12 6 13.87 3.16 6 1.34 (n = 3) 2.03 6 0.77 (n =3 )
2) A478D 83.67 6 5.33 0.69 6 0.27 (n = 6) 3.14 6 1.37 (n =3 )
3) V715A 83.00 6 5.29 0.53 6 0.28 (n = 3) 1.73 6 0.53 (n =4 )
4) V715G 96.33 6 3.18 0.28 6 0.16 (n = 3) 2.35 6 1.99 (n =3 )
5) G716D 66.67 6 5.24 2.39 6 1.90 (n = 6) 2.37 6 1.32 (n =4 )
6) T888P 54.33 6 5.33 0.38 6 0.30 (n = 3) 1.30 6 0.44 (n =3 )
7) G1384E 101.80 6 8.50 0.17 6 0.09 (n = 4) 1.64 6 0.49 (n =4 )
8) S1387F 83.91 6 5.30 0.84 6 0.17 (n = 4) 4.05 6 1.34 (n =4 )
9) S1387Y 83.13 6 5.38 2.46 6 0.96 (n = 4) 2.44 6 0.42 (n =4 )
10) S1389Y 70.00 6 7.81 1.26 6 0.73 (n = 4) 1.65 + 0.63 (n =3 )
11) A1458T 94.33 6 10.48 0.52 6 0.21 (n = 3) 1.06 6 0.37 (n =3 )
12) Q1459H 91.00 6 2.31 0.69 6 0.39 (n = 3) 1.32 6 0.29 (n =3 )
13) E1517K 72.88 6 5.85 1.73 6 0.39 (n = 3) 1.96 6 0.55 (n =4 )
Mean of dominant
diazoxide-unresponsive
SUR1 mutations
84.6 6 4.64 (n = 13) 1.42 6 0.35 (n = 13)* 1.83 6 0.18 (n = 13)†
Mean of dominant
diazoxide-responsive
SUR1 mutations
91.05 6 5.67 (n = 10) 15.26 6 5.06 (n = 10) 19.96 6 6.29 (n = 10)
Wild type 100 61.19 6 5.53 (n = 11) 77.8 6 2.2 (n =9 )
Data are means 6 SE. *Compared with the dominant diazoxide-responsive group, P = 0.0002. †Compared with the dominant diazoxide-
responsive group, P = 0.0003.
FIG. 4. Responsiveness of dominant diazoxide-unresponsive and domi-
nant diazoxide-responsive SUR1 mutations. Responses to diazoxide and
MgADP of expressed KATP channels containing diazoxide-unresponsive
SUR1 mutations (black circles) and diazoxide-responsive SUR1 muta-
tions (gray squares) are compared. Diazoxide-unresponsive mutations
are labeled according to numbers in Table 2. Diazoxide-responsive
mutations are as follows: A, D310N; B, R370G; C, R1353H; D, K1374R;
E, G1478V; F, G1479R; G, S1386P; H, R1539Q; I, I1512T; and J, E1507K.
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missense mutations of SUR1 that act in a recessive fashion
show that they interfere with normal surface expression of
channels by preventing trafﬁcking of channels from the
endoplasmic reticulum to the plasma membrane (5,14). In
contrast, both types of dominant SUR1 mutations, when
expressed in vitro, permit the normal assembly of chan-
nels and subsequent trafﬁcking to the plasma membrane.
Once at the surface, the difference between diazoxide-
unresponsive dominant mutations and diazoxide-responsive
mutations appears to be their degree of residual respon-
siveness to activation by MgADP and diazoxide. Stimu-
lated potassium channel currents were reduced to only
1–2% of normal in the diazoxide-unresponsive mutations
such as S1387Y, whereas the responsive mutations such
as R1539E retain about 20% of normal channel activities.
Under simulated heterozygous expression conditions, the
diazoxide-unresponsive mutation S1387Y also exhibited
decreased responses to MgADP and diazoxide when
compared with the diazoxide-responsive mutant R1539E,
although the difference was not as pronounced (Fig. 3E).
As shown in Fig. 4, however, there was a small overlap
between the two types of mutations, making it difﬁcult
to differentiate them completely by in vitro expression
studies.
An interesting feature of the dominant, diazoxide-
responsive KATP mutations we previously reported was the
high frequency of asymptomatic carriers (7). This was also
true of the diazoxide-unresponsive group, despite the fact
that the affected children appeared to be more severely
affected, as reﬂected by their younger age of onset (Fig. 1
and Table 1). The diazoxide-unresponsive, dominant muta-
tion case subjects closely resemble patients with recessive
KATP defects, in which patients with biallelic mutations al-
most always present in the ﬁrst days of life. We have en-
countered one patient with a homozygous, recessive SUR1
mutation who escaped detection until 18 months of age, but
such examples are extremely rare. Because KATP channels
are hetero-octamers containing four subunits of SUR1 and
four of Kir6.2, it is attractive to speculate that dominant
KATP defects act as dominant negatives to impair function of
channels containing one or more mutant subunits. Using
concatemers to express channels containing from zero to
four subunits of a mutant SUR1 associated with neonatal
diabetes, Babenko (19) recently reported that the activation
of channel activity increased with increasing numbers of
mutant subunits. We previously speculated that the small
percentage of channels formed entirely of wild-type sub-
units might account for diazoxide responsiveness of domi-
nant KATP mutations (7). However, the present series of
diazoxide-unresponsive dominant defects demonstrate that
this explanation of “spare channels” is not sufﬁcient. The
reasons for the lack of symptoms in some carriers with
dominant SUR1 mutations might include nongenetic fac-
tors, such as chance exposure to fasting stress or protein
meals, or possibly epigenetic modiﬁers. It should, however,
be noted that the SUR1
2/2 mouse model has only a mild
hypoglycemia phenotype (20,21), suggesting that genetic de-
ﬁciency of KATP function alone may not be sufﬁcient to al-
ways cause readily appreciated symptomatic hypoglycemia.
The data strongly support the idea that the single
mutations found in the patients in this report all act in
dominant fashion. Evidence of dominant transmission
from affected parent to affected child occurred only once,
and the series by Flanagan et al. (9) also included a similar
case. The present series also included several instances in
which de novo mutations were associated with disease in
multiple affected individuals, consistent with a dominant
mode of action. For some of the de novo mutations in our
series, there was no additional clinical genetic evidence to
support a dominant mode of action. The in vitro mutation
expression data, however, provide strong evidence in favor
of dominant action for all of the mutations studied; when
expressed with wild-type Kir6.2, the mutations produced
channels that trafﬁcked to the plasma membrane but had
markedly reduced responses to Mg-ADP or diazoxide.
In summary, these observations expand the range of hy-
perinsulinism disorders that can be associated with inacti-
vating missense mutations of the b-cell KATP channel. These
missense mutations may be 1) recessive, 2) dominant and
diazoxide-responsive, or 3) dominant and diazoxide un-
responsive. In our series, the third group made up 17% of
the children who required surgery for diffuse hyperinsu-
linism associated with SUR1 mutations. In vitro expression
studies may often be necessary for determining which
category a mutation ﬁts. Because many KATP mutations
associated with hyperinsulinism are novel, information
about the speciﬁc functional effect of a mutation is in-
creasingly necessary for accurate genetic diagnosis. The
present results suggest that dominant mutations of SUR1
may be a relatively common cause of hyperinsulinism in
children whose hypoglycemia cannot be controlled by
usual medical management.
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